GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Life Sciences Ltd (BOM:530239) » Definitions » Revenue

Suven Life Sciences (BOM:530239) Revenue : ₹84.15 Mil (TTM As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Suven Life Sciences Revenue?

Suven Life Sciences's revenue for the three months ended in Sep. 2024 was ₹25.73 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was ₹84.15 Mil. Suven Life Sciences's Revenue per Share for the three months ended in Sep. 2024 was ₹0.12. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was ₹0.39.

Warning Sign:

Suven Life Sciences Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Suven Life Sciences was -36.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -18.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was -43.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was -42.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Suven Life Sciences's highest 3-Year average Revenue per Share Growth Rate was 50.20% per year. The lowest was -72.00% per year. And the median was 3.60% per year.


Suven Life Sciences Revenue Historical Data

The historical data trend for Suven Life Sciences's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Life Sciences Revenue Chart

Suven Life Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 144.15 134.78 118.44 135.39 116.93

Suven Life Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.60 24.51 23.85 10.06 25.73

Competitive Comparison of Suven Life Sciences's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suven Life Sciences's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's Revenue distribution charts can be found below:

* The bar in red indicates where Suven Life Sciences's Revenue falls into.



Suven Life Sciences Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹84.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suven Life Sciences  (BOM:530239) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Suven Life Sciences Revenue Related Terms

Thank you for viewing the detailed overview of Suven Life Sciences's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Suven Life Sciences Business Description

Traded in Other Exchanges
Address
Avenue 7, Road No. 5, Banjara Hills, Number 8-2-334, 6th Floor, SDE Serene Chambers, Hyderabad, TG, IND, 500 034
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.

Suven Life Sciences Headlines

No Headlines